ArticleOncotarget2017
Cytotoxic lanostane-type triterpenoids from the fruiting bodies of Ganoderma lucidum and their structure-activity relationships.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Medicinal Mushroom Supplements in Cancer: A Systematic Review of Clinical Studies.Current oncology reports · 2023Pooled it
- From Remedy to Therapy: Confronting the Bioavailability Bottleneck inPharmaceuticals (Basel, Switzerland) · 2026Review
- CanPharmaceuticals (Basel, Switzerland) · 2025Review
- Genome-wide identification of CYP450 in Ganoderma lucidum and expression analysis of genes related to ganoderic acid synthesis.Archives of microbiology · 2025Article
- Review
- Unveiling triterpenoid superiority in a newly developedFrontiers in nutrition · 2025Article
- The Anti-Melanogenic Effects of Ganodermanontriol from the Medicinal MushroomMolecules (Basel, Switzerland) · 2024Article
- Functional properties of Ganoderma lucidum supplementation in canine nutrition.Journal of animal science · 2024Article
- Influence of cultivation substrate on antioxidant activities and triterpenoid profiles of the fruiting body ofFrontiers in nutrition · 2024Article
- Exploring the Potential Medicinal Benefits ofFoods (Basel, Switzerland) · 2023Review
- A critical review on submerged production of mushroom and their bioactive metabolites.3 Biotech · 2020Review
- Natural Compounds in Sex Hormone-Dependent Cancers: The Role of Triterpenes as Therapeutic Agents.Frontiers in endocrinology · 2020Review
- Article
- High-Pressure Supercritical COFrontiers in pharmacology · 2020Article
- Ganoderiol F purified fromCell cycle (Georgetown, Tex.) · 2019Article
- Alcohol Extracts FromFrontiers in pharmacology · 2019Article
- Anticancer Activity ofCancers · 2018Article
- Characterizing novel anti-oncogenic triterpenoids from ganoderma.Cell cycle (Georgetown, Tex.) · 2018Article
- Article
- Hypouricemic Effects ofFrontiers in pharmacology · 2017Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We conducted a study of Ganoderma lucidum metabolites and isolated 35 lanostane-type triterpenoids, including 5 new ganoderols (1-5). By spectroscopy, we compared the structures of these compounds with known related compounds in this group. All of the isolated compounds were assayed for their effect against the human breast carcinoma cell line MDA-MB-231 and hepatocellular carcinoma cell line HepG2. Corresponding three-dimensional quantitative structure-activity relationship (3D-QSAR) models were built and analyzed using Discovery Studio. These results provide further evidence for anti-cancer constituents within Ganoderma lucidum, and may provide a theoretical foundation for designing novel therapeutic compounds.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.